Based on the Silo Pharma Inc stock forecast from 0 analysts, the average analyst target price for Silo Pharma Inc is not available over the next 12 months. Silo Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Silo Pharma Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Silo Pharma Inc’s stock price was USD 0.43. Silo Pharma Inc’s stock price has changed by -17.69% over the past week, -61.96% over the past month and -81.39% over the last year.
No recent analyst target price found for Silo Pharma Inc
No recent average analyst rating found for Silo Pharma Inc
Company Overview Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore; and has joint development agreement with Kymanox for the design and development of a subcutaneous insertion device for SP-26. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. Read Less
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses...Read More
Frequently Asked Questions About Silo Pharma Inc (SILO) Stock
Stock Target Advisor's fundamental analysis for Silo Pharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on SILO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SILO's stock to indicate what its average analyst target is.
SILO stock's Price/Earning ratio is 0.83.
Our analysis grades SILO stock's Price / Earning ratio at B-. This means that SILO stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this SILO may be undervalued for its sector.
The last closing price of SILO's stock was USD 0.43.
The most recent market capitalization for SILO is USD 4.82M.
Unfortunately we do not have enough analyst data on SILO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Silo Pharma Inc's stock.
As per our most recent records Silo Pharma Inc has 3 Employees.
Silo Pharma Inc's registered address is 677 N. Washington Boulevard, Sarasota, FL, United States, 34236.
You can get more information about it from Silo Pharma Inc's website at https://silopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Silo Pharma Inc (SILO) Stock
Stock Target Advisor's fundamental analysis for Silo Pharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on SILO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SILO's stock to indicate what its average analyst target is.
SILO stock's Price/Earning ratio is 0.83.
Our analysis grades SILO stock's Price / Earning ratio at B-. This means that SILO stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this SILO may be undervalued for its sector.
The last closing price of SILO's stock was USD 0.43.
The most recent market capitalization for SILO is USD 4.82M.
Unfortunately we do not have enough analyst data on SILO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Silo Pharma Inc's stock.
As per our most recent records Silo Pharma Inc has 3 Employees.
Silo Pharma Inc's registered address is 677 N. Washington Boulevard, Sarasota, FL, United States, 34236.
You can get more information about it from Silo Pharma Inc's website at https://silopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SILO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
